Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Genzyme Gains Approval From Brazil For Monoclonal Antibody Lemtrada

Genzyme Corp., a biotechnology company and an unit of Sanofi (SNY: Quote), Friday said ANVISA, Brazil's national health surveillance agency, has approved Lemtrada for the treatment of patients with relapsing forms of multiple sclerosis to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.

While Mexico, Canada, Australia and EU have approved Lemtrada, FDA has rejected the compound, a decision Genzyme intends to appeal in the future.

The development of the compound included two randomized Phase 3 studies, as well as an ongoing study. The first study, CARE-MS I, compared treatment using Lemtrada with high-dose subcutaneous interferon beta-1a (Rebif) in patients with RRMS who had active disease or were new to treatment. The second study, CARE-MS II, involved patients who had relapsed while on prior therapy.

In CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, said the company. The company also said that in CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada versus interferon beta-1a.

The side-effects of Lemtrada include infusion-associated reactions, infections (upper respiratory tract and urinary tract), lymphopenia and leukopenia. Autoimmune conditions and serious infections can occur in patients receiving Lemtrada.

The first course of Lemtrada is administered through IV on five consecutive days, and the second course is administered on three consecutive days, 12 months later.

Register
To receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Denis Mukwege, a doctor from the Democratic Republic of Congo, has won this year's Sakharov Prize for Freedom of Thought for helping thousands of gang rape victims in the country. The award was instituted by the European Parliament, and the laureate for 2014 was selected by EP President Martin Schulz and the political group leaders. Announcing Europe's top human rights prize Tuesday, Schulz said Stocks moved sharply higher over the course of the trading day on Tuesday, extending the recovery from the sell-off seen in recent weeks. The Nasdaq and the S&P 500 closed higher for the fourth consecutive session but remain well off their mid-September highs. Despite indications that the spread of Ebola inside the U.S. has been contained, the results of a new Gallup poll show the deadly disease had made its debut on a list of the top 10 most important problems facing the country.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.